NSPR
InspireMD, Inc.
There isn't enough reported data to score NSPR yet.
NSPR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
NSPR's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NSPR PE Valuation
NSPR has no meaningful PE right now: it lost money over the past year.
NSPR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect NSPR's losses to shrink, with revenue growing.
NSPR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.61 | +$0.20 |
| Q1 2026 | -$0.70 | +$0.07 |
| Q4 2025 | -$0.76 | $0.00 |
| Q3 2023 | -$1.54 | +$0.71 |
| Q2 2023 | -$1.97 | +$0.23 |
| Q1 2023 | -$2.32 | -$0.25 |
| Q4 2022 | -$2.36 | -$0.33 |
NSPR is still losing money, but far less than before: $0.61 per share over the past year, against $2.36 at its worst in late 2022.
NSPR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.8M | -0.4% |
| Q1 2026 | $3.4M | +122% |
| Q4 2025 | $3.1M | +62% |
| Q3 2025 | $2.5M | +39% |
| Q2 2025 | $1.8M | +2.2% |
| Q1 2025 | $1.5M | +1.2% |
| Q4 2024 | $1.9M | +11% |
| Q3 2024 | $1.8M | +16% |
NSPR's revenue is growing: $2M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -816% | -83 points |
| Q1 2026 | -411% | +338 points |
| Q4 2025 | -384% | +97 points |
| Q3 2025 | -517% | -50 points |
| Q2 2025 | -732% | -257 points |
| Q1 2025 | -750% | -259 points |
| Q4 2024 | -481% | -151 points |
| Q3 2024 | -468% | -105 points |
NSPR's operating margin was −816% last quarter, down 83 points from the same quarter a year ago, near the bottom of its range since 2019.
NSPR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$11.2M | -$2.3M |
| Q1 2026 | -$12.5M | -$3.4M |
| Q4 2025 | -$9.7M | -$2.7M |
| Q3 2025 | -$9M | -$2.8M |
| Q2 2025 | -$8.9M | -$4.1M |
| Q1 2025 | -$9.2M | -$3.9M |
| Q4 2024 | -$7.1M | -$2.7M |
| Q3 2024 | -$6.1M | -$2M |
NSPR has burned cash in almost every quarter: −$42M over the past year, against −$31M the year before.
NSPR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +858K shares |
| 1 year | +69% | +34.7M shares |
| 3 years | +980% | +76.8M shares |
| 5 years | +9914% | +83.8M shares |
NSPR has 85M diluted shares, up 69% from a year ago.
NSPR Net Leverage
NSPR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NSPR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.4 | Neutral |
| Stochastic | 36.1 | Neutral |
NSPR's weekly RSI is 47 (neutral) and its Stochastic is 36 (neutral).
NSPR PE vs Healthcare Sector
NSPR has no meaningful PE right now: it lost money over the past year.
NSPR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.58 | 33% above |
| 20 week MA | $0.70 | 10% above |
| 50 week MA | $1.15 | 33% below |
| 100 week MA | $1.84 | 58% below |
| 200 week MA | $2.14 | 64% below |
NSPR has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 64% below its 200-week average.
NSPR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.4 | $5.55 | -61% |
| 2021 | $5.55 | $3.27 | -41% |
| 2022 | $3.27 | $0.90 | -72% |
| 2023 | $0.90 | $2.81 | +212% |
| 2024 | $2.81 | $2.69 | -4.3% |
| 2025 | $2.69 | $1.95 | -28% |
| 2026 YTD | $1.95 | $0.77 | -61% |
NSPR's yearly returns have swung widely, from +212% in 2023 to −72% in 2022. It's down 61% so far in 2026.